Cinclus Pharma Holding AB is hosting a virtual event featuring Professor Prateek Sharma to discuss the treatment landscape and unmet medical needs for erosive GERD patients, highlighting their drug ...

STOCKHOLM, Aug. 18, 2021 /PRNewswire/ -- Cinclus Pharma Holding AB ("Cinclus Pharma"), a biopharmaceutical company focused on the development of a novel treatment for severe gastroesophageal reflux ...

A RECENT episode of the popular BBC programme Countryfile, which featured the dipper on a Scottish river, drew me back in time to a former workplace and my first ever encounter with Cinclus cinclus ...

Cinclus Pharma reported a net sales increase to TSEK 9,744 for Q3 2025, but faced an operating loss of TSEK -44,122. Despite the financial losses, the company maintains a robust cash position with ...

This is a preview. Log in through your library . Abstract The time-activity budget and energy expenditure of a riverine bird, the dipper Cinclus cinclus, was studied from March 1988 to July 1989, ...

The mating system of the Eurasian dipper (Cinclus cinclus) involves males defending resources, such as nesting sites or food, and females choosing sites based on quality. Strong territoriality and ...

Cinclus Pharma reported quarterly financial results showing a cash position of SEK 540 million at the end of Q3 2025, down from SEK 589 million in Q2. The company generated revenues of SEK 10 million ...

STOCKHOLM, March 4, 2020 /PRNewswire/ -- Cinclus Pharma Holding AB ("Cinclus Pharma") announced today that the company has successfully completed a financing round of SEK 250 million to fund the ...

"Cinclus Pharma has now entered late-stage clinical development following the initiation of its first Phase III study, and patient recruitment has so far progressed well. Topline results are expected ...

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company developing the next generation of treatments for acid-related diseases, today announced the initiation of its Phase III ...

Former Sanofi subsidiary Zentiva has signed off on up to 220 million euros for the rights to commercialize and manufacture an ex-AstraZeneca asset for gastric-acid-related diseases in Europe. Under ...